Clinical trial · Observational
Role of the Gut Microbiome in Anti-tumor Therapy Induced Diarrhea
NCT05873231CI-TRIAL-00097938TKIrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The role of the gut microbiome in the development of side effects of anti cancer treatment will be assessed in this longitudinal cohort study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- gut microbiome composition
- timeFrame
- 4-12 weeks
- description
- 16s sequencing
Secondary outcomes (6)
- measure
- stool zonulin
- timeFrame
- 4-12 weeks
- description
- ELISA
- measure
- stool calprotectin
- timeFrame
- 4-12 weeks
- description
- ELISA
- measure
- serum lipopolysaccharide binding protein
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years or older * Start of a systemic anti-cancer therapy * Informed consent Exclusion Criteria: * • Pre-existing diarrhoea * Antibiotic therapy -4 to -1 week before inclusion * Probiotic treatment -4 to -1 week before inclusion * Inability to give informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.